ARPA-H puts $160M into bespoke drug therapies; Biohaven switches up scientific leadership

An article from

News roundup

The ARPA-H program could provide researchers with a roadmap to develop personalized gene editing drugs. Elsewhere, a Botox rival succeeded against migraines and two deals were struck.

Published July 10, 2026

Getty Images

ARPA-H puts $160M into bespoke drug therapies; Biohaven switches up scientific leadership

Other newsrooms on this story

Related reading

ARPA-H launches $160 million effort to develop custom gene editing drugs

ARPA-H bookmarks $160M for custom gene editing treatments. Is it enough?

Arbutus, Sanofi escalate mRNA patent fights; InnoCare’s TYK2 contender advances

Roche ends Huntington's gene-silencing programs

Ipsen succeeds in migraine trials; Tarsus buys iRenix for $75M upfront

UCB to acquire maker of antibody treatments for autoimmune diseases